Safety aspects of gadofosveset in clinical practice – analysis of acute and long-term complications

AbstractPurpose rpose of this retrospective study was to systematically search for acute adverse reactions and long-term complications in all patients that had been administered gadofosveset at our hospital. als and methods ntified 67 gadofosveset administrations during 2006–2009 in 62 patients from 8 to 84 years of age. Radiological information system (RIS) and clinical patient records were analyzed for suspected acute adverse reactions and long-term complications including nephrogenic systemic fibrosis (NSF). dofosveset doses ranged between 0.024 and 0.060 mmol/kg bodyweight with a mean dose of 0.031-mmol/kg bodyweight. Follow-up time of the patients ranged from less than 1 year up to 4 years with a mean follow-up time of 2.1 years. s te adverse events or technical failures related to the contrast medium were recorded in the RIS. No dermatological and nephrological diseases related to the gadofosveset administration were found in the clinical patient records. Four patients died during follow-up without any apparent relation to the gadofosveset exposure. sions on our clinical material we conclude that gadofosveset is safe for a mixed patient population with no acute adverse events or any indications of long-term complications during the follow-up time up to four years.